SEC Form 4 · accession 0001209191-18-011324
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Brett Primiano
Officer — EVP, CBO, GC & Secretary
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 15, 2018 | S | 1,014 | $15.0187 | D | 8,867 | D | |
| Common StockF3 | Feb 16, 2018 | S | 1,486 | $15.0054 | D | 7,381 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price.
- F3Represents the weighted average sale price. These shares were sold in transactions at $15.00 and $15.08. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price.